Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Neuroendocrine Tumors 15Thyroid Neoplasms 10Thyroid Cancer, Papillary 10Adenocarcinoma, Follicular 9Paraganglioma 4Adrenocortical Carcinoma 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Somatostatinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

Ifosfamide 2Filgrastim 2Doxorubicin 2selurampanel 1Radiotherapy 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Chemotherapy, Adjuvant 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Endometrial Stromal × Magnetic Resonance Spectroscopy × Endocrine × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡